Literature DB >> 1515828

Follow up of patients presenting with fatigue to an infectious diseases clinic.

M Sharpe1, K Hawton, V Seagroatt, G Pasvol.   

Abstract

OBJECTIVES: To determine the symptomatic and functional status during follow up of patients referred to hospital with unexplained fatigue and to identify patient variables associated with persistent functional impairment.
DESIGN: Follow up by postal questionnaire six weeks to four years (median 1 year) after initial clinical assessment of patients referred to hospital during 1984-8.
SETTING: Infectious diseases outpatient clinic in a teaching hospital. PATIENTS: 200 consecutive patients with fatigue of uncertain cause for at least six weeks; 177 fulfilled the inclusion criteria. MAIN OUTCOME MEASURES: Findings at initial assessment; current symptoms, beliefs about the cause of illness, coping behaviours emotional disorder, social variables including membership of self help organizations, and degrees of recovery and functional impairment from questionnaire responses.
RESULTS: 144 (81%) patients returned completed questionnaires. Initial assessment did not indicate the cause of fatigue, other than preceding infection. The proportion of patients with functional impairment was significantly smaller with longer follow up (33% (11/33) at two to four years, 73% (29/40) at six weeks to six months; chi 2 for trend = 12.5, df = 1; p less than 0.05). Functional impairment was significantly associated with belief in a viral cause of the illness (odds ratio = 3.9; 95% confidence interval 1.5 to 9.9), limiting exercise (3.2; 1.5 to 6.6), avoiding alcohol (4.5; 1.8 to 11.3), changing or leaving employment (3.1; 1.4 to 6.9), belonging to a self help organization (7.8; 2.5 to 23.9), and current emotional disorder (4.4; 2.0 to 9.3).
CONCLUSIONS: Short term prognosis for recovery of function was poor but improved with time. Most patients had made a functional recovery by two years after initial clinic attendance. Impaired functioning was more likely with certain patient characteristics. Prospective studies are required to clarify whether these associations are the consequences of a more disabling illness or indicate factors contributing to impaired function.

Entities:  

Mesh:

Year:  1992        PMID: 1515828      PMCID: PMC1883193          DOI: 10.1136/bmj.305.6846.147

Source DB:  PubMed          Journal:  BMJ        ISSN: 0959-8138


  21 in total

Review 1.  Psychiatric management of PVFS.

Authors:  M Sharpe
Journal:  Br Med Bull       Date:  1991-10       Impact factor: 4.291

2.  Comparison of the General Health Questionnaire and the Hospital Anxiety and Depression Scale.

Authors:  G Lewis; S Wessely
Journal:  Br J Psychiatry       Date:  1990-12       Impact factor: 9.319

3.  Routine full blood counts as indicators of acute viral infections.

Authors:  D F Nixon; A J Parsons; R P Eglin
Journal:  J Clin Pathol       Date:  1987-06       Impact factor: 3.411

4.  Acetylcholine receptor antibody as a diagnostic test for myasthenia gravis: results in 153 validated cases and 2967 diagnostic assays.

Authors:  A Vincent; J Newsom-Davis
Journal:  J Neurol Neurosurg Psychiatry       Date:  1985-12       Impact factor: 10.154

5.  The hospital anxiety and depression scale.

Authors:  A S Zigmond; R P Snaith
Journal:  Acta Psychiatr Scand       Date:  1983-06       Impact factor: 6.392

6.  The functioning and well-being of depressed patients. Results from the Medical Outcomes Study.

Authors:  K B Wells; A Stewart; R D Hays; M A Burnam; W Rogers; M Daniels; S Berry; S Greenfield; J Ware
Journal:  JAMA       Date:  1989-08-18       Impact factor: 56.272

7.  Chief complaint fatigue: a longitudinal study from the patient's perspective.

Authors:  E Nelson; J Kirk; G McHugo; R Douglass; J Ohler; J Wasson; M Zubkoff
Journal:  Fam Pract Res J       Date:  1987

8.  Depression among patients with a chief complaint of chronic fatigue.

Authors:  P Manu; D A Matthews; T J Lane; H Tennen; V Hesselbrock; R Mendola; G Affleck
Journal:  J Affect Disord       Date:  1989 Sep-Oct       Impact factor: 4.839

9.  Chronic fatigue in primary care. Prevalence, patient characteristics, and outcome.

Authors:  K Kroenke; D R Wood; A D Mangelsdorff; N J Meier; J B Powell
Journal:  JAMA       Date:  1988-08-19       Impact factor: 56.272

10.  A report--chronic fatigue syndrome: guidelines for research.

Authors:  M C Sharpe; L C Archard; J E Banatvala; L K Borysiewicz; A W Clare; A David; R H Edwards; K E Hawton; H P Lambert; R J Lane
Journal:  J R Soc Med       Date:  1991-02       Impact factor: 18.000

View more
  24 in total

1.  How should we manage fibromyalgia?

Authors:  P A Reilly
Journal:  Ann Rheum Dis       Date:  1999-06       Impact factor: 19.103

Review 2.  Recovery from infectious mononucleosis: a case for more than symptomatic therapy? A systematic review.

Authors:  Bridget Candy; Trudie Chalder; Anthony J Cleare; Simon Wessely; Peter D White; Matthew Hotopf
Journal:  Br J Gen Pract       Date:  2002-10       Impact factor: 5.386

3.  Outcome in the chronic fatigue syndrome.

Authors:  H Cope; A S David
Journal:  BMJ       Date:  1992-08-08

4.  Serotonin, gastric emptying, and dyspepsia.

Authors:  M H Duncan
Journal:  BMJ       Date:  1992-09-05

5.  Outcome in the chronic fatigue syndrome.

Authors:  C Shepherd
Journal:  BMJ       Date:  1992-08-08

6.  Outcome in the chronic fatigue syndrome.

Authors:  S Wessely
Journal:  BMJ       Date:  1992-08-08

7.  Self help organization's advice on myalgic encephalomyelitis.

Authors:  M C Hume
Journal:  BMJ       Date:  1992-09-12

8.  Treating chronic fatigue with exercise. Exercise, and rest, should be tailored to individual needs.

Authors:  E Goudsmit
Journal:  BMJ       Date:  1998-08-29

9.  Abnormalities of sleep in patients with the chronic fatigue syndrome.

Authors:  R Morriss; M Sharpe; A L Sharpley; P J Cowen; K Hawton; J Morris
Journal:  BMJ       Date:  1993-05-01

10.  Chronic fatigue syndrome: a follow up study.

Authors:  D Bonner; M Ron; T Chalder; S Butler; S Wessely
Journal:  J Neurol Neurosurg Psychiatry       Date:  1994-05       Impact factor: 10.154

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.